Abstract The purpose of this review is to provide a comprehensive overview of reported methods for screening and confirmation of the low-molecular-weight compound and drug of abuse gamma-hydroxybutyric acid (GHB) in biological fluids. The polarity of the compound, its endogenous presence, its rapid metabolism after ingestion, and its instability during storage (de novo formation and interconversion between GHB and its lactone form gamma-butyrolactone) are challenges for the analyst and for interpretation of a positive result. First, possible screening procedures for GHB are discussed, including colorimetric, enzymatic, and chromatography-based procedures. Confirmation methods for clinical and forensic cases mostly involve gas chromatography (coupled to mass spectrometry), although liquid chromatography and capillary zone electrophoresis have also been used. Before injection, sample-preparation techniques include (a combination of) liquid-liquid, solid-phase, or headspace extraction, and chemical modification of the polar compound. Also simple "dilute-and-shoot" may be sufficient for urine or serum. Advantages, limitations, and trends are discussed.
Introduction
Gamma-hydroxybutyric acid (GHB) or 4-hydroxybutanoic acid, a short chain fatty acid (pK a 4.6-4.8) with two polar substituent groups (hydroxyl and carboxyl), was synthesized in the early sixties as a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) that could cross the blood-brain barrier [1, 2] . GHB was also found to be endogenously present in humans as a minor precursor and metabolite of GABA. Its function as an endogenous compound remains unclear; it probably acts as a neuromodulator or neurotransmitter via GABA B receptors and GHB-specific receptors in the brain [3] . GHB can also be formed in humans from the precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) ( Fig. 1) [4, 5] .
The sodium salt of GHB, sodium oxybate, has been used therapeutically as an anesthetic, but this use has been abandoned in most countries because of side effects such as seizures and amnesia [6] . Furthermore, GHB and/or GBLcontaining supplements were sold to increase body muscles-because it is assumed GHB stimulates growthhormone release-and to improve sleep, but these supplements have been withdrawn from the market since the late nineties after reports of abuse and side effects. Nonetheless, sodium oxybate is currently being used for treatment of narcolepsy with cataplexy and excessive daytime sleepiness (Xyrem) and of alcohol (Alcover, Italy) and opiate withdrawal [7] .
In addition, illegal GHB and its precursors, GBL and 1,4-BD, have become popular amongst clubbers because of their stimulating effects. The club drug is known under street names as liquid ecstasy, Georgia Home Boy, Grievous Bodily Harm, soap, scoop, and salty water [8] . GHB and its precursors are most commonly available as solutions, in small vials or in bottles mixed with, e.g., water, from which typically a capful is ingested orally per dose [4] . GHB abuse has also been reported in drug-facilitated sexual assaults (DFSA), because of its strong sedative and amnesic effects. The possibility of rendering a victim unconscious is enabled by the chemical properties of GHB-a colorless liquid which can be easily mixed with other liquids [9, 10] .
A dose typically ingested for abuse ranges from 2 to 6 g GHB, corresponding to 25 to 75 mg kg −1 body weight. [5] .
Euphoria, relaxation, increased sociability, and reduced psychomotor skills are among the effects experienced when using GHB; these effects are similar to those reported for moderate alcohol intoxication [5] . GHB has a steep dose-response curve, with a narrow margin between therapeutic or desired and toxic effects [5, 11, 12] . Also, the effects reported after recreational use of GHB and its precursors are dual, i.e. both sedative and stimulatory, depending on the dose. An individual dose of 1.0 to 2.0 g that is ingested orally results in effects such as relaxation and euphoria whereas doses of 2.5 to 3 g may lead to side-effects such as nausea and vomiting. Higher doses (3 to 4 g) may result in loss of consciousness and a dose of more than 4 g can result in respiratory depression and coma [13] . Finally, side effects of a severe intoxication may evolve to convulsions, coma, and death. Fatal incidents have been reported as a result of the use of GHB alone or in combination with other drugs, for example alcohol and ecstasy [11] . First reports of abuse appeared in the early 1990s [12, 14] . Since the late 1990s and early 2000s the incidence of GHB intoxication has apparently been decreasing worldwide. For example, when GHB exposure reported to the California Poison Control System from 1999 to 2003 was evaluated, a decrease was recorded; this may reflect the true incidence, but may also be because of a decrease in adverse events without a decrease in overall GHB use; it may also be a result of random variability [14] . According to annual reports of the latest drug situation and trends in the European Union and Norway, published by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), national estimates of the prevalence of GHB-where they exist-remain low. For example, in the UK, 2 % of regular clubbers reported last year use of GHB in an Internet survey [15] . Furthermore, GHB screening using automated clinical analyzers was not routinely available until 2009. In addition, because of the rapid elimination of GHB from the human body, delayed sampling may result in GHB concentrations below current cut-off values, thus no longer enabling proof of ingestion [16] . Therefore, true case incidence may be underestimated [5] . Moreover, more recent Fig. 1 Structures of gammahydroxybutyric acid (GHB; a), gamma-hydroxyvaleric acid (GHV; b), gamma-aminobutyric acid (GABA; c), betahydroxybutyric acid (BHB; d), alpha-hydroxybutyric acid (AHB; e), gamma-butyrolactone (GBL; f), gamma-valerolactone (GVL; g),1,4-butanediol (1,4-BD; h), ethylene glycol (EG; i), and diethylene glycol (DEG; j) reports show that recreational use with limited awareness of the possibility to suddenly fall into a coma has resulted again in an increase in GHB intoxication at raves or other dance parties [11, 17] .
Although general use may be relatively low compared with other drugs of abuse, for example cannabis, amphetamines, and cocaine, higher use has been observed in subpopulations (e.g. men having sex with men), settings, and geographical areas [18, 19] . One should consider the possibility of GHB intoxication in cases of unexplained coma (in the absence of a head injury or elevated head pressure). Treatment of GHB overdose is primarily supportive, focusing on preservation of respiratory status, with no known antidote available [4] . Complete recovery has usually been observed after 6-8 h, with a typical abrupt awakening of the patient [20] . Furthermore, after frequent ingestion (every 1 to 3 h, around-the-clock) dependence has been observed, and withdrawal symptoms such as agitation, anxiety, tachycardia, hypertension, and delirium. These symptoms begin 1 to 6 h after the last dose and can last for 5 to 15 days [21, 22] .
Since the late 1990s, the Food and Drug Administration (FDA) has banned all non-prescription sales of GHB. Illicit GHB is, since 2000, a Schedule I agent (Controlled Substances Act) in the US. In 2002 the FDA approved the use of sodium oxybate for treatment of narcolepsy with cataplexy (Xyrem), so it has become available on prescription as a Schedule III agent. Also, in 2005, the European Medicines Agency (EMA) approved sodium oxybate for treatment of narcolepsy with cataplexy. On the other hand, GBL is a List I controlled chemical, used for the manufacture of a controlled substance-GHB-making its possession, manufacture, or sale with the intention of ingestion illegal. The latter also applies to gamma-valerolactone (GVL) and 1,4-BD. So, the congeners of GHB are easily and, moreover, legally available on e.g. the internet, as long as the use is not intended for ingestion [4, 14] .
A variety of bioanalytical methods for GHB determination has been reported since the early 1970s [23] [24] [25] [26] . This review will focus primarily on those methods published since the 1990s, when there was an emerging need for analytical methods to measure GHB in biological fluids as part of toxicological investigations, given the first reports of GHB abuse appearing in the US [27] . Also trends, advantages and disadvantages of sample preparation and analytical techniques are discussed. First, according to the generally applied strategy in toxicology, the socalled systematic toxicological analysis (STA), screening techniques including, e.g., colorimetric and enzymatic tests, will be discussed. These differentiate between (presumably) positive and negative GHB samples. Positive GHB results are then confirmed by use of a second, independent method, mostly involving quantification [28] . This has been achieved mostly by gas chromatography (GC), although liquid chromatography (LC) and capillary zone electrophoresis (CZE) have also been used.
Analytes of interest
Although in a toxicological context it might be relevant to determine whether GHB positivity is the result of intake of GHB, GBL, or 1,4-BD, GHB remains the most important analyte to search for in biological fluids, owing to the rapid in-vivo biotransformation of its precursors [29, 30] . Also after fatalities involving consumption of large amounts of these precursors, high GHB and only low GBL and 1,4-BD levels have been observed [31] . Other compounds that might be of interest for simultaneous determination (i.e. in the same run) are the positional isomers and isobaric compounds alpha and betahydroxybutyric acid (AHB, BHB; Fig. 1 ) (diabetic and post-mortem cases) [32] [33] [34] [35] , glycols (in emergency cases with coma of unknown origin when ingestion of GHB or ethylene glycol (EG) is suspected, the latter also causing high anion gap metabolic acidosis; Fig. 1 ) [35] [36] [37] , and other club drugs, for example MDMA, ketamine [38] , and gamma-hydroxyvaleric acid (GHV) or its lactone, GVL (reported to be a GHB alternative) [31, 39] (Fig. 1) .
It must be kept in mind that a quantitative result may be affected by the in-vitro interconversion of GHB and GBL in aqueous matrices, the equilibrium depending on pH and temperature [40] . Therefore, several methods have evaluated the rate of GHB and/or GBL conversion during sample treatment or analysis, with different outcomes. Overall, three scenarios have been described. First, conversion to either GBL or GHB was complete and was used for GHB determination [8, 41, 42] . This implies that GHB is measured as "total GBL" (GHB converted to GBL+ actual GBL present in the sample) or as "total GHB" (actual GHB present in the sample +GBL converted to GHB). In these scenarios, GHB and GBL are completely converted to GBL and GHB, respectively, before analysis [8, 41, 42] . Second, conversion did not occur, so absolute GHB was measured [16, 35, 36] ; last, conversion occurred but was minimal, with little or no relevance in the forensic or clinical setting [43, 44] . Therefore, the method of analysis must be considered when comparing data from, e.g., post-mortem analyses. In methods involving conversion of GHB to GBL (first scenario), slightly higher GHB concentrations may be observed (measured as "total GBL", i.e. GHB converted to GBL+actual GBL present in the sample) than in methods determining absolute GHB. This may be because of conversion to GBL of some of the (endogenous) GHB present in post-mortem plasma or urine during storage, depending on sample pH [45, 46] .
GHB concentrations and matrices of interest
As mentioned above, the natural presence of GHB results in measurable baseline levels in a variety of biological matrices. Studies have been conducted on, e.g., urine [47] [48] [49] [50] , plasma [49] , serum [50] whole blood [32, 48, 49] , and oral fluid [51] samples obtained from healthy non-users. Data from non-GHB related fatalities [45, 52] and concentrations arising from exogenous administration have also been collected. Ingestion can be intentionalfor recreational or therapeutic use-or accidental; both may lead to overdoses or even fatalities, as illustrated by several case reports [11, [53] [54] [55] [56] . Physiological concentrations of GHB, situated in the low and sub-microgram-permilliliter range, are mostly well below concentrations found in intoxicated patients, for whom there is a narrow range between recreational doses and overdoses. An overlap between highly toxic and lethal concentrations has been observed, with high inter-individual variability of the relationship between measured GHB concentration and effect [13, 57] . According to the list of therapeutic and toxic concentrations from The International Association of Forensic Toxicologists (TIAFT), a value above 280 μg mL −1 GHB in plasma may be sufficient to cause death [58] . In addition, elevation of GHB concentrations during storage of urine and blood has been reported, further complicating interpretation of a GHB concentration. Appropriate storage of samples until analysis is therefore required (recommendation: −20°C) [9, 13, 46, 57, 59] . De-novo formation in post-mortem blood has also been reported. For more detailed information about GHB production in post-mortem cases we refer the interested reader to the literature [45, 52, 60, 61] .
To differentiate between endogenous and exogenous concentrations [49] , cut-off levels have been established. Most authors agree on a 10 μg mL −1 cut-off level for GHB in ante-mortem urine [48, 49, 59] , although suggestions of 5 [62] [32] . This implies that screening and confirmation methods for GHB in ante-mortem urine, whole blood, and plasma should, ideally, have a decision limit or lower limit of quantification (LLOQ) below or equal to 4 or 5 μg mL −1 . Higher cut-off levels have been proposed for post-mortem matrices (20 for urine, 30 and 50 for whole blood, and 12 μg mL −1 for vitreous humor) to exclude false positives [16, 37, 52] . For following up GHB concentrations in Xyrem patients, a wide concentration range may be necessary, depending on the timing of sampling (shortly after intake vs. several hours later) [63] . Endogenous presence of GHB in biological matrices not only renders true blank matrices unavailable for conducting method validation experiments, it also precludes the use of low calibrators (<1 μg mL −1 ) prepared in authentic matrices [33] , and complicates interpretation of a positive result.
As an alternative to the use of interpretative cut-off concentrations, continuous-flow GC-combustion-isotope-ratio MS has been used to discriminate between exogenous (i.e. synthetic) and endogenous GHB in blood. Initial findings suggest different 13 C and 12 C content of the endogenous and synthetic form of GHB [64] . However, it is obvious that the cost and complexity associated with this complex technique severely limits its general applicability.
In addition to the endogenous presence and possible instability of GHB during storage, samples must be collected as soon as possible after ingestion, because of the extensive metabolism of GHB once ingested orally (plasma T 1/2 less than 1 h) [5, 65, 66] . Otherwise, GHB concentrations in blood and urine will drop to endogenous levels within 6 to 12 h after intake, no longer enabling proof of intake of GHB, possibly leading to underestimation of the total number of positive cases [16] . Therefore, alternative sampling strategies and alternative matrices have been evaluated. These include dried blood spots (DBS), i.e. capillary whole blood obtained by fingerprick, facilitating sample collection, and unconventional matrices such as sweat and oral fluid. Only moderate results have been obtained by use of the latter two matrices because diffusion of the acidic drug in these has been shown to be limited. After GHB intake (50 mg kg −1 sodium GHB, n=5), only 1/4 to 1/3 of the concentration found in plasma was measured in oral fluid, with an even quicker return to baseline values and high oral fluid and plasma inter-variability. GHB concentrations in sweat were only slightly higher than baseline values [44, [66] [67] [68] [69] [70] . Hair analysis has, in contrast, been shown useful for extending the window of detection, because of incorporation of GHB in the hair matrix. A case report has described detection of DFSA even after a single use only [71] . Also in hair, endogenous GHB is present, often rendering it difficult to draw straightforward conclusions. Therefore, small segments are analyzed to detect elevation of baseline GHB concentration as a result of exogenous ingestion [72, 73] . More than 95 % of an oral dose of GHB is converted to CO 2 and H 2 O as it enters the Krebs cycle via succinate, with less than 5 % being excreted "unchanged" in urine [5] . Until recently, no specific metabolites of GHB were known. However, Petersen et al. [74] demonstrated the existence of a new metabolite, GHB-glucuronide, in urine, in concentrations ranging from 0.11 to 5.0 μg mL −1 . Although more research, for example pharmacokinetic studies after GHB administration, are required, this compound is theoretically a biomarker of GHB exposure with the potential to extend the window of detection in the conventional matrix urine [74] .
Procedures for screening for the presence of GHB in biological fluids A good screening procedure enables simple, sensitive, selective, and rapid identification of unknown analytes in a minimal amount of sample. STA approaches typically use immuno-and/ or enzymatic assays to screen for analytes or categories of compounds, then GC-mass spectrometry (GC-MS) or highperformance liquid chromatography-diode array detection (HPLC-DAD) for high-throughput simultaneous detection of as many toxic compounds as possible. Liquid chromatography-mass spectrometry (LC-MS) or tandem mass spectrometry (LC-MS-MS) and high-resolution techniques have been used to a lesser extent for such comprehensive screening but are gaining increasing interest nowadays, sometimes even replacing the immunological and/or enzymatic tests [28, 75, 76] . An overview of possible screening procedures for GHB is given below, starting with colorimetric tests. Given the lack of commercially available immunoassays, STA using chemical analyzers did not include GHB until 2009 [16, 34] . Since then, an enzymatic assay adaptable to common analyzers has become commercially available (Bühlmann Laboratories, Switzerland) [77] . Furthermore, several GC methods became available and recently LC-MS-MS-based methods have been reported with the focus on high-throughput, so both techniques can also be used for screening. A screening method preferably has a decision limit (cut-off of the applied assay) at or below the exogenous and/or endogenous cut-off, to enable reliable initial differentiation between samples considered to be GHB-positive or negative. However, because GHB concentrations in moderately to severely intoxicated GHB patients, for example those brought to an emergency department in a comatose state, will usually be well above these cut-off levels, we also consider in this review methods with decision limits and/or LLOQs (well) above these cut-offs as screening methods. As with any screening test, a positive result should only be regarded as a preliminary indication and must be confirmed by use of an independent, preferably MS-based, technique, for example GC-MS or LC-MS(-MS).
Colorimetric tests
Badcock and Zotti [78] reported a colorimetric test that enables identification of GHB in human urine on the basis of the conversion of GHB to GBL. Briefly, after addition of concentrated sulfuric acid, ammonium sulfate, and nitroprusside to 250 μL urine, an intense and instant blue-olive-green color will appear if GHB is present in the sample [78] . Another colorimetric test, a modification of the ferric hydroxamate test for ester detection, only requires 5 min to detect GHB in 0.3 to 1 mL urine, the presence of GHB being indicated by purple coloring of the sample [79] . Although both colorimetric tests are simple and results can be obtained in less than 10 min, the prime disadvantage is the lack of sensitivity, with limits of detection of 100 or even 500 μg mL −1 [78, 79] .
Enzymatic assays
Enzymatic assays to determine GHB are based on oxidation of GHB to succinic semi-aldehyde (SSA), a reaction that occurs during metabolism in vivo via the enzyme GHBdehydrogenase (GHB-DH).
Colorimetric enzymatic assays
Bravo et al. [80] developed a solution-endpoint and a dipstickassay for determination of GHB in human urine. Identification was possible by coupling the oxidation reaction of GHB, via cloned and isolated GHB-DH, to a reduction reaction of a tetrazolium pro-dye, resulting in the formation of a colored product (absorbance at 450 nm). Although these tests are easy to perform, providing enough sensitivity remains a critical issue, only ensuring 100 % true positives when a minimum of 100 μg mL −1 GHB is present in urine.
Another test strip, commercially available from Drugcheck, can detect GHB in human urine with a cut-off level of 10 μg mL . Results are obtained within 10 min, and a color chart on the test strip is used for interpretation, next to a test strip for vitamin C, a compound with cross-reactivity with the GHB test. Although this GHB test strip is more sensitive, detecting lower GHB concentrations, only a preliminary result is provided, without indication of the degree of intoxication [81] .
Enzymatic kit
It became clear from the tests mentioned above that more sensitive, semi-quantitative, rapid, and simple screening to detect GHB in urine and serum was urgently needed. To this end, an enzymatic kit was commercialized in 2009 [77] . This kit also utilizes a recombinant GHB-DH to oxidize GHB to SSA, while the co-factor nicotinamide adenine dinucleotide (NAD + ) is simultaneously reduced to NADH+H + , which absorbs at 340 nm. The test is adaptable to common clinical chemistry analyzers and requires only 10 μL sample. Quantification is performed by using two calibrators and two quality controls provided by the manufacturer; the working range is from 5 to 250 μg mL GHB is commonly ingested with alcoholic beverages [11] . A cut-off level of 10 μg mL −1 for serum and 15 μg mL −1 for urine has been proposed [82, 83] . Grenier et al. [84] evaluated use of this enzymatic assay as a screening method for forensic matrices including whole blood and vitreous humor. When correlating results for a variety of cases (sexual assaults, impaired drivers, and deaths) with those from a GC-MS reference method, no false negatives and few false positives were observed, with post-mortem samples seeming to be more prone to testing false positive than ante-mortem samples. Although whole blood required protein precipitation with acetonitrile before analysis, analyst time savings can still be substantial compared with chromatography-based procedures. In addition, although very efficient GC-MS and LC-MS-MS procedures have been developed for GHB, integration with other tests on automated analyzers makes this assay valuable for (clinical) toxicology labs. However, Grenier et al. [84] found that a limitation of this test is that it may not be applicable to other matrices, e.g. vitreous humor, because of the high incidence of false positives.
In summary, this test may be valuable for emergency screening of urine and serum for forensic applications and for other screening purposes [83] .
Other screening techniques 1 H nuclear magnetic resonance (NMR) spectrometry has been used to detect GHB in urine and serum [85] and in oral fluid (600 μL) [75] . This technique is non-destructive and, because little or no sample preparation is required, is less laborintensive than other techniques. Similarly, ion mobility spectrometry (IMS) has promise as a screening method for GHB and related compounds in urine [86] . Via direct injection using a split-splitless injector and thermal desorption, the sample was brought directly into the IMS configuration without chromatographic separation, reducing analysis time and resulting in an estimated detection limit of 3 μg mL
In addition, CZE with indirect ultraviolet (UV) detection is capable of detecting high concentrations of GHB in urine after simple 1:4 dilution with water. Calibration curves ranged from 80 to 1,280 μg mL −1 [87] . For detection, indirect UV absorption using a chromophore in an electrolyte solution was necessary, because the native molecule GHB has poor UV absorption [88, 89] . Small adaptations of analytical conditions (co-ion, pH, etc.) further improved method sensitivity and selectivity and enabled the analysis of not only urine but also serum after 1:8 dilution with 3 mmol L −1 NaOH, completely converting GBL to GHB (calibration curve ranged from 25 to 500 μg mL
) [90] . Although accurate and precise results may be obtained by use of CZE, the LLOQ is relatively high (ranging from 25 to 80 μg mL −1 and 5 to 60 μg mL −1 , depending on urine density), compared with chromatographic techniques (LLOQ ranging from 0.1 to 8 μg mL
−1
). Therefore, these CZE-based methods are regarded as more suitable as an alternative screening method for a GHB overdose, being rapid and simple, rather than as a secondary confirmatory method.
Chromatographic screening techniques
Compared with colorimetric and enzymatic assays, chromatographic assays typically require more intensive and timeconsuming sample preparation, for example derivatization or conversion to GBL (see below). For example, Lebeau et al. [8] opted for a gas chromatography-flame ionization detection (GC-FID) screening method using headspace (HS) as injection technique after conversion of GHB to GBL; confirmation of GHB (as GBL) was by GC-MS. Also, in clinical practice, in which the objective is to achieve medical diagnosis and start treatment, non-specific detection such as by GC-FID is sufficient, as stated by Blanchet et al. [42] . These authors determined GHB after derivatization with BF 3 -butanol.
Similarly, urinary organic acid assays based on silylation and GC-MS, more readily available than GHB assays in hospital laboratories, were investigated for detection of GHB in urine. However, if these methods included acidification of the samples during sample treatment, which favors conversion of GHB to GBL, only a small GHB peak was visible, as might be expected [91] . In addition, silylated urea may elute close to/ co-elute with silylated GHB, having, in addition, similar MS properties. Therefore, it may be important to eliminate the urea interference by adding an urease treatment step to the sample-preparation procedure, enabling identification of GHB with higher confidence [92] [93] [94] .
In addition, chromatographic methods used to screen for a variety of compounds, including GHB, have been reported. Rasanen et al. [95] developed a headspace in-tube extraction GC-MS method to screen for hydroxylated methylderivatized organic acids, including GHB, in urine and extracted whole blood. In addition, a GC-MS method for simultaneous screening of urine for 128 date-rape drugs, including GHB, 1,4-BD, and GBL (using silylation), has been reported by Adamowicz and Kala [96] .
An LC-MS-MS method for screening of DBS from newborns for elevated GHB concentrations has recently been reported. This enables diagnosis of SSADH deficiency, a rare inherited metabolic disorder in which GHB concentrations are increased because of a deficiency of the succinic semialdehyde dehydrogenase enzyme responsible for conversion of SSA to succinate [68] . Although not intended for toxicology purposes, this method may also be applicable to screening of DBS for exogenous GHB [97, 98] .
In addition to these screening methods, several authors have reported simplified and rapid procedures for highthroughput determination of GHB, leading to the possibility of using confirmation methods for screening as well. Here, we mention only examples of these methods in which sample preparation is reduced or minimal. Details can be found in the next section and in Table 1 . For example, Van hee et al. [36] determined GHB (and glycols) in small volumes of plasma and urine (20 μL) by use of GC-MS, by adding excess silylation reagent directly to the biological sample. This procedure was recently modified by Meyer et al. [35] , who used microwave-assisted derivatization; this is another approach particularly useful in the laboratories of hospital emergency departments, because quantitative results for urine can be obtained within 30 min by use of one-point calibration. Other examples of procedures with minimum hands-on time are those in which derivatization reagents are applied directly "on spot" (for DBS) or "in-vial" (in HS sampling) [41, 44, 67] . More recently, a multi-analyte ultra-high-performance LC-MS-MS (UHPLC-MS-MS) method has been reported which may also be useful for screening because of easy sample preparation and resulting high-throughput [99] .
Confirmation methods for clinical and forensic cases
Methods suitable for confirmation of an assumed GHBpositive sample ideally have an LLOQ below or at the proposed cut-off level, should be selective for GHB, and, if they deliver quantitative results, these should be reliable and accurate. Because it may be necessary to confirm the presence of GHB in more complex biological matrices and because more sophisticated chromatographic techniques are used, sample preparation becomes more important. Sample work-up is usually more complicated than that used for colorimetric or enzymatic methods, which are primarily suitable for urine and serum. Below, an overview of commonly used samplepreparation procedures is given, followed by an overview of the analytical techniques used to separate and detect GHB (and analogues). Table 1 provides an overview of the different published procedures. To evaluate if a given method enables differentiation between exogenous and endogenous GHB, the calibration range with the quantification limit is included. Also the choice of internal standard may affect data quality and has, therefore, also been included in the table [100] . As shown in the table, several compounds with similarity to GHB have been used as internal standards. In MS-based methods, use of a deuterated internal standard is recommended to compensate for variations during sample preparation and analysis. The deuterated form of GHB, GHB-d6, has been used widely for this purpose; a C-labeled internal standard is not yet commercially available.
Sample preparation
The techniques used to treat biofluids comprise dilution, filtration, deproteinization, chemical modification, liquid-liquid extraction (LLE), solid-phase extraction (SPE), and HS extraction, sometimes alone but usually combined. These sample preparation procedures are often regarded as timeconsuming and there has been a tendency to reduce manual sample handling by introducing new, fully automated techniques. It should be mentioned that the latter implies longer method development times and new skill requirements and may not always be implementable in smaller laboratories [101] . Furthermore, starting from the more traditional procedures, simplified extractionless procedures have been proposed, for example dilution and direct derivatization ("on spot" and "in-vial"), together with microwave-assisted derivatization and on-line derivatization techniques, for example injection port derivatization. Some of these simplifications have been made possible by the introduction of improved separation and detection techniques, for example tandem MS, resulting in procedures with minimal hands-on time. In addition, the initial sample volume required for analysis may be reduced without loss of method sensitivity. The latter also depends on GHB recovery, a method property worth evaluating during optimization of sample treatment. Recovery should be reproducible and sufficient in terms of method sensitivity. Therefore, examples of strategies affecting recovery are also mentioned below.
Dilution and filtration of the biological fluid
If appropriate separation and detection techniques are used, simple dilution of urine and serum, with or without subsequent filtration, may be sufficient as sample preparation [34, 99, 102] . This has been demonstrated for several LC-MS-MS methods capable of quantifying GHB with sufficient sensitivity in these matrices. In addition, possible extraction difficulties arising from the hydrophilic nature of GHB are avoided. For example, urine has been diluted 1:20 [34] and 1:1 [99] with water, and 1:10 with acidic 10 % MeOH [102] before LC-MS-MS analysis. As an alternative, urine and serum have been diluted 1:4 with a buffer solution before CZE analysis with contactless conductivity detection (CZE-C 4 D) [103] . It is important to note that sensitivity must be sufficient, as illustrated by Wood et al. [34] , who compared method sensitivity (measured as signal-to-noise ratio, S/N) for two samplepretreatment procedures before LC-MS-MS analysis. The first of these procedures was 1:20 dilution of urine (with deionized water containing internal standard); the second was based on a more time-demanding SPE extraction (OASIS Table 1 Overview of confirmation methods for determination of GHB in biological fluids, in alphabetic order and sorted by analytical technique (GC, LC, and other) GC (Unless specified: GC-MS, 1 μL injected in splitless injection, ionization mode EI, and helium as carrier gas. *If method includes conversion of GHB to GBL without acidification of the sample, determination of original GBL concentration is possible)
Ref. Comparison with GC-FID method [45] Screening GHB Urine (50 μL) Dilution: 1 mL water, mix, + 3 mL water SPE (SAX, CUQAX 6 mL 500 mg):
conditioning: 3 mL methanol, 3 mL water; sample loading; washing: 3 mL deionized water, 3 mL methanol; elution: solid-phase dynamic extraction; SPE: solid-phase extraction; SPME: solid-phase micro-extraction; SSA: succinic semi-aldehyde; TBCS: tert-butyldimethylchlorosilane; TFAA: trifluoroacetic acid anhydride; TMCS: trimethylchlorosilane; UHPLC: ultra-high performance liquid chromatography; UV: ultraviolet cartridges). Although an approximately twofold increase in sensitivity was obtained by use of the SPE cartridges, the authors were still able to use the simpler dilution method, because it readily enabled measurement of endogenous GHB levels. Although this "dilute-and-shoot" approach is simple and convenient, with a minimum of hands-on time, assessment of matrix effects is strongly advised, as in any LC-MS-MSbased procedure, because matrix components may strongly affect ionization of GHB in the MS source. To compensate for any effect of the matrix, a stable isotopically labeled internal standard should be included in the procedure [34] . Assuming similar alteration of the response of this internal standard, matrix effects can be compensated for.
In addition, samples have been diluted to reduce the effect of the original matrix during sample treatment and analysis. For example, the effect of the matrix during solid-phase micro-extraction (SPME) may be reduced by diluting the original sample [38, 104] . Similarly, samples have been diluted with water before LLE [105, 106] or SPE [99, [107] [108] [109] . For example, Elian et al. [107] assumed that a 50-μL sample and synthetic urine, consisting of inorganic salts and proteins in an aqueous medium, would act similarly to 50 μL deionized water if these were all diluted in 4 mL water before SPE. As a consequence, calibrators and controls could be prepared in water instead of blank matrix, which is especially of interest for GHB endogenously present in human samples.
Deproteinization of the biological fluid
For such compounds as GHB with low protein binding, protein precipitation is an adequate and easy technique for removal of a variety of interferences present in blood and plasma, for example blood cells, proteins, and lipids, before analysis [32, 99] . To illustrate, Shima et al. [32] compared protein precipitation with a variety of SPE and LLE techniques for clean-up of urine, and found that protein precipitation led to the highest GHB recovery and cleanest chromatograms. Generally, there are four protein-precipitation techniques: addition of organic solvents, acids, salts, and metal ions [110] . As far as we are aware, only the first three have been used for GHB analysis.
As organic solvents, acetonitrile [16, 35, 37, [111] [112] [113] [114] , methanol (MeOH) [32, 115] , a combination of both (ice-cold acetonitrile-MeOH 85:15v/v [99, 109] ), acetone [31, 116] , and water-MeOH (3:97, v/v) [117] have been used. Placing samples in a freezer for at least 10 min before centrifugation may promote complete precipitation [99] .
Organic solvents and acids have also been used simultaneously to improve protein precipitation and, in addition, GHB recovery. For example, addition of sulfuric acid during protein precipitation with acetonitrile was found to increase the recovery of GHB from 50 to 90 % [5, 33, 66] . Similarly, acidified methanol has been used for whole-blood protein precipitation [102] .
Cold perchloric acid [27, 29, 54] has been added to plasma, thereby combining deproteinization and lactone formation (see below). Finally, anhydrous sodium sulfate (Na 2 SO 4 ) has been added to biological fluids, for protein precipitation and salting-out, before HS-trap analysis [41] . Similar to the above mentioned "dilute-and-shoot" approach, it is important to evaluate matrix effects, particularly when protein precipitation is (almost) the only sample-preparation technique before LC-MS-MS analysis. For example, when blood or serum were subjected to protein precipitation, with subsequent centrifugation and 1:1 dilution of the supernatant with acidified water before LC-MS-MS analysis, approximately 40 % suppression of the GHB signal was observed. Again, the importance of using of a deuterated internal standard, for example GHBd6, is emphasized, because doing so can compensate for the matrix effect [102] . As far as we are aware, only three sample-preparation procedures consist merely of protein precipitation before LC-MS-MS injection, and for only two of these have matrix effects been evaluated [113, 114, 117] . For example, one procedure that did evaluate matrix effects reported 16 to 27 % enhancement of GHB ionization which was compensated for by use of GHB-d6 [117] .
Chemical modification of GHB
Because GHB is a polar (sometimes anionic) molecule, with lactone formation occurring at high injector-port temperatures or induced chemically (at low pH), chemical modification before GC is necessary for reliable quantification [75, 118] . For GC analysis, two major strategies have been used: lactone-formation by addition of acid or derivatization by use of a variety of derivatization reagents. Formation of a derivative before LC analysis and detection has also proved useful; however, it has been applied to a lesser extent than before GCbased applications. Both strategies-lactone formation and derivatization-may improve the extraction properties of GHB and/or chromatographic analysis, as discussed in more detail below. Figure 2 gives a schematic overview of possible derivatization procedures, with the resulting derivatives of GHB, using common derivatization reagents.
Chemical modification to improve extraction GHB undergoes intra-molecular esterification within minutes in an acidic environment [40] and the GBL formed is more easily extracted from biological matrices than GHB. Lactone formation has been accomplished by addition of 6 mol L −1 hydrochloric acid (urine [27, 29, 119] ), concentrated sulfuric acid [8, 120] , 20 % trifluoroacetic acid [121] , or 1.6 or 0.8 mol L −1 perchloric acid (plasma [27, 29] ) to plasma, urine or oral fluid. If perchloric acid is added to plasma, lactone formation and deproteinization are performed in a single step. Subsequently, the acidified sample, or the supernatant after centrifugation [27, 29] are left at room temperature [119, 120] for 5 min [8] , at 80°C for 20 min [27, 29] , or at 75°C for 1 h [121] to enable complete conversion. As a consequence, differentiation between the initial GBL present in the sample and the GBL formed as a result of acid-induced cyclization of GHB is no longer possible [105] , unless two aliquots of the same sample are analyzed, one with and one without acid treatment [8, 29] . In addition, derivatization reagents suitable for "insitu" or "in-vial" derivatization can be added directly to the sample matrix, thereby enabling analysis of the samples by solid-phase micro extraction (SPME) or HS-based extraction (and injection) techniques by forming a more volatile derivative of GHB. Hexyl chloroformate, in the presence of pyridine as catalyst, has been used to derivatize the carboxyl group of GHB [38, 104] , and dimethyl sulfate (DMS) in alkaline medium has been used to modify both functional groups [41, 95] .
To overcome difficulties encountered when extracting the hydrophilic and small analyte GHB in those methods requiring derivatization, extractionless derivatization procedures have been reported. In addition to an expected improvement in recovery, sample preparation time and organic solvent waste are reduced. Van hee et al. [36] were the first to report extractionless sample preparation, based on direct derivatization of GHB in biofluids with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA). Addition of excess derivatization reagent to a 20-μL sample of biofluid (serum, plasma, urine) resulted in a simple and rapid method with sufficient sensitivity for routine toxicological analysis. Similarly, starting from 1 μL oral fluid, an extractionless procedure with direct derivatization has been reported, enabling determination of exogenous GHB concentrations [69] . Furthermore, GHB has been derivatized directly ("on spot") in DBS with a mixture of trifluoroacetic acid (TFAA) and heptafluorobutanol (HFB-OH), thereby enabling omission of the extraction step [44, 67] . Chemical modification to improve chromatographic analysis and detection Apart from improving or facilitating extraction, chemical modification may also improve chromatographic analysis and detection. The GC properties of GHB are improved by conversion to the more volatile and stable lactone-form of GBL, achieved by using the same procedures as to improve extraction via GBL formation (see above). Second, a variety of derivatization reagents have been used to increase its molecular weight, at the same time reducing its polarity, thereby enhancing volatility, separation efficiency, and/or selectivity, and, consequently, method sensitivity. As shown in Table 1 , silylation is widely used to derivatize GHB off-line in GC-based applications. Mainly BSTFA [2, 5, 16, 31-33, 35, 36, 43, 49, 50, 59, 60, 62, 66, 69, 91, 111, 112, 122-124, 126] has been applied, then N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) [105, 115, 125] and N-(tert-butyldimethylsilyl)-Nmethyltrifluoroacetamide (MTBSTFA) [37, 106] . By use of these reagents, the hydroxyl and carboxyl functional groups of GHB are derivatized simultaneously, and lactone formation is avoided because acidic conditions are not used [32] . Moreover, to avoid GBL formation and GHB losses during evaporation, Kimura et al. [91] made urine alkaline before derivatization, producing the non-volatile salt form of GHB. Furthermore, the resulting di-trimethylsilyl derivative of GHB (Fig. 2) can be injected directly into the GC-MS, without removal of excess reagent. Of course, the latter requires increased maintenance of the injection port and MS source to prevent contamination between runs. Another issue is the possibility of co-eluting di-TMS urea, requiring baseline separation of GHB and the urea di-TMS derivative under the GC conditions used. As silylating reactions mostly require heating for 5 to 30 min, injection-port [106] and microwave assisted silylation [35] can be valuable alternatives which reduce analysis time. Also the aforementioned derivatization reactions improve chromatographic analysis and detection.
Although derivatization is primarily known for its use in GC applications, it may also be used in LC-based separations. For example, to enable fluorescence detection (FD) the carboxyl group has been derivatized by adding 4-bromomethyl-7-methoxycoumarin (Br-MMC) to a water-free sample residue in the presence of dibenzo-18-crown-6-ether, acting as a catalyst, to improve the reaction yield [89] . Furthermore, butylation of the carboxyl function of GHB by use of HCl-n-butanol improved detection by ion-trap mass spectrometry [127] .
Liquid-liquid extraction (LLE) of GHB or GBL
Liquid-liquid extraction of GHB Solvents commonly used to extract GHB from biological fluids include ethyl acetate [2, 49, 50, 59, 60, 62, 106, [122] [123] [124] [125] [126] [127] , t-butyl methyl ether [105, 127] , and hexane [43] . Because the physical properties of GHB make it a poor candidate for LLE, a variety of approaches have been used to enhance transfer of the GHB to the organic solvent (hence increasing its recovery). GHB must be in the uncharged, i.e. neutral, form for optimum extraction yield and selectivity, which are affected by the choice of solvent, pH, and additives [101] . Therefore, the charge on the carboxylic group (pK a 4.6-4.8) has been influenced by addition of 0.1 mol L −1 HCl or cold 0.05 mol L −1 H 2 SO 4 to urine, serum, and blood, which enhances its transfer to ethyl acetate [59, 122, 127] . Also, for whole-blood, Pan et al. [37] reported the use of a water-scavenging material, for example 80:20 dimethoxypropane-N,N-dimethylformamide, to facilitate GHB extraction. Salting-out, to increase the ionic strength of the aqueous phase, improving partitioning of relatively water-soluble analytes between two immiscible phases, has also been reported [105] . For this purpose, saturated salt solutions, for example saturated ammonium chloride buffer [51, 124, 126] , have been added to the test tubes or NaCl (solid salt) has been added before extraction [105] .
Liquid-liquid extraction of GBL After lactone formation (see above), GBL has been extracted from biologic fluids with dichloromethane [8] , chloroform [119, 121] , or benzene [27] , solvents preferably avoided in the modern laboratory. Because GBL may be protonated under the acidic conditions required for complete conversion, recovery can be improved by adding sodium chloride to the solution for salting-out purposes, but also by neutralizing (pH 6-7) the initial acidic pH (pH 1) by addition of, e.g., phosphate buffer or sodium hydroxide [27, 121] . After LLE, the mixture is usually centrifuged and the supernatant subsequently concentrated, but not completely evaporated, because GBL may be lost during evaporation to dryness, being more volatile than the free acid [92] . As an example, it was found essential to evaporate with low nitrogen flow and at a low temperatures (max 35°C) to avoid unacceptable losses of GBL [27] .
Solid phase extraction (SPE) of GHB
The first type of SPE sorbent used to extract GHB from biofluids was (strong) anion exchange. When using this type of cartridge, the classical SPE procedure of conditioning, loading, washing, drying, and eluting has been followed. Interaction is based on ion-exchange chemistry whereby the organic moiety or quaternary ammonium material bonded to the solid matrix maintains its positive charge over the whole pH range, enabling pH-dependent interaction with GHB. At neutral pH, the carboxyl group will be negatively charged (pK a 4.6-4.8), and will interact with the positively charged sorbent. To elute GHB, it is necessary to neutralize its negative charge by use of an acidic elution solvent [107, 108, 128] .
In addition, SPE cartridges can also be used to retain interfering substances, enabling the analyte of interest to pass through the sorbent and be collected for further analysis. For this purpose, Clean Screen SPE cartridges have been used to clean vitreous humor, blood, and urine. The collected eluate contained GHB without substances that could interfere during subsequent analysis [31, 43, 125] . In addition, a (strong) cation-exchange sorbent can be used for clean-up of whole blood after protein precipitation. Introducing this additional clean-up resulted in improved peak shape of GHB and in reduced baseline noise [99, 109] .
An advantage of SPE is that it can be automated more easily than current precipitation or derivatization techniques, which typically require off-line manual operations [107] . To illustrate this, automated SPE (Oasis HLB 30) using a 96-well plate has recently been used for extraction of GHB from whole blood after protein precipitation [99] . Combining this automated SPE with LC-MS-MS resulted in a highthroughput method suitable for screening more than 6,000 samples a year [99] .
Also SPME, as a modification of the more classical SPE, has been introduced. In contrast with conventional extraction methods, which use multi-step techniques and excess organic solvents, SPME consists of one solvent-free step only for concentration of the analytes of interest. This technique has been used to determine GHB (derivatized with hexyl chloroformate) in urine, by use of a fused-silica fiber coated with a stationary phase which adsorbed the analytes of interest. The SPME fiber can be placed directly in the sample or, alternatively, in the headspace [38, 104] . (Headspace extraction of GHB is discussed below.)
Headspace extraction of GBL or derivatized GHB
Few of the GC methods presented use HS as extraction and injection technique. The reason may be not only the more complex optimization of these procedures but also the fact that, typically, a larger sample volume is required to achieve sensitivity similar to that of more traditional sample preparation procedures, for example LLE or SPE [29, 104] . Also the requirement for a more specific configuration, which may also imply use of a more specific analytical column (Table 1) limits its general use. Nonetheless, these techniques have the advantage that GHB, in a derivatized form or as GBL, can be extracted directly from the aqueous sample, requiring fewer manual operations, being fully automatable, consuming less solvent (being solvent-free), and saving technical time [38, 104] . Sample preparation is mostly limited to adding the sample, anhydrous salt (to enhance transfer of the analyte of interest to the headspace, thus increasing its recovery), and derivatization reagent or acid for lactone formation to an HS vial. After appropriate sealing, the vial can be placed in the HS oven for analysis.
Headspace extraction of derivatized GHB Combining "invial" derivatization with headspace injection techniques may extend the range of application normally reserved for volatile compounds to semi-volatile or non-volatile analytes such as GHB. After derivatization with hexyl chloroformate or dimethyl sulfate, derivatized GHB has been extracted by SPME or HS-trap, respectively [38, 41, 95] . Both methods have little sample-preparation time. The method using SPME is one of the most sensitive methods reported, having an LLOQ of 0.1 μg mL −1 , starting from 0.5 mL urine. The HS-trap method is suitable for determination of GHB in a variety of biological fluids, requiring only 100 μL sample.
Headspace extraction of GBL A static HS method described for determination of GHB is based on LLE of 1 mL urine or whole blood, followed by conversion to GBL [8] . Headspace SPME and solid-phase dynamic extraction (SPDE) have also been used to determine GHB as total GBL in plasma and urine, resulting in methods with sufficient sensitivity (LLOQ from 1-5 μg mL
) but requiring relatively large samples (ranging from 0.5 to 1.0 mL) compared with other sample-preparation techniques (0.02-0.5 mL) [29, 120] .
Chromatographic analysis and detection

Gas chromatography
Although the nature of GHB does not favor use of GC (see above), it remains the most popular separation technique of the last two decades, enabled by use of appropriate sample preparation techniques. Toxicological analysis is commonly performed with an analytical column containing a polysiloxane stationary phase with 95 % methyl groups and 5 % phenyl groups, which is also well suited for determination of derivatized GHB and/or GBL (and analogues), reflected in its wide use. Most GC-based methods focus on the detection of GHB, either in the derivatized form or as GBL; a few methods also include simultaneous analysis of glycols, BHB, GHV, 1,4-BD, and/or SSA [2, 31, 35, 36, 39, 123] .
Gas chromatography-flame ionization detection Although this universal detector has been used for initial screening for GHB, followed by confirmation using GC-MS [8, 56] , Jones et al. [116] used GC-flame ionization detection (FID) to quantify GHB as GBL in blood within a wide calibration range, starting at 8 μg mL −1
.
Gas chromatography-mass spectrometry To unequivocally identify and quantify GHB in biological fluids, GC is preferably used in conjunction with mass spectrometry. It has been used with electron impact (EI) ionization and in positive or negative chemical-ionization modes (PICI or NICI). For quantification, the MS operates in SIM (selected ion monitoring) mode, in which ions of m/z typical of GBL or derivatized GHB are monitored. Derivatization using silylating or other derivatizing reagents, to increase the molecular weight and the fragments' masses, is generally advantageous for MS detection, because more selective ions are formed than those formed from GBL (m/z 42, 56, and 86 in EI mode). In addition, fragmentation of the di-TMS-derivative via CI instead of EI results in mass spectra with more abundant and higher-molecular-weight ions [59] . PICI has been used by Kerrigan [59] and Chen et al. [111] to quantify GHB in biofluids after silylation, and by Lenz et al. [120] and Frison et al. [29] after conversion of GHB to GBL. Although one method had a lower LLOQ of 0.4 μg mL −1 , no relevant gain in sensitivity was observed compared with GC methods in which the MS is used in EI mode. On the other hand, using the MS in NICI mode to quantify GHB as GBL in plasma has been shown suitable for determination of endogenous concentrations, with a calibration range situated in the low μg mL −1 range [119] .
Although not routinely performed using GC-based methods, simultaneous analysis of GHB and 1,4-BD or other compounds, for example BHB and SSA, is possible, as was done by Lora-Tamayo et al. and Sakurada et al., [2, 123] respectively, who only slightly modified the method of Couper and Logan [122] . GHV and GHB can be analyzed simultaneously [31] , and Andresen-Streichert et al. [39] recently reported a GC-MS method for simultaneous analysis of GHB and GHV in urine, with an extraction and derivatization procedure based on the method published by Kerrigan [59] .
Gas chromatography-tandem mass spectrometry Coupling tandem MS to GC enables the monitoring of a selected transition from a parent ion to (a) specific daughter ion(s), which may reduce the requirement for time-consuming sample clean-up. However, although very high sensitivity as a result of increased selectivity may be valuable for hair analysis, the advantage of being able to detect low GHB levels by MS-MS is not crucial for blood and urine, because GHB is endogenously present at relatively high concentrations (sub and low microgram-per-milliliter range). Nonetheless, MS-MS may still result in improved peak shape, which is required for reliable integration [33] . Although tandem MS may have the advantage over existing methods of providing spectra free from background contaminants, and, thus, of being more selective, it remains or becomes even more important to evaluate whether the di-TMS derivative of GHB is free from interferences from compounds with the same precursor ion (m/z 233), for example its positional isomers, AHB and BHB [33] .
Liquid chromatography
Few confirmatory methods use LC to determine GHB in biofluids. This may be for historical reasons, because GC has been longer and more widely available for routine analysis in toxicological laboratories, but also for practical reasons, because poor retention of the native molecule on classical reversed-phase (RP) columns is expected. Nonetheless, LC techniques may have advantages over GC methods. For example, although similar sensitivity can be obtained, workload and use of toxic solvents may be reduced, because the introduction of tandem MS has resulted in simpler sample preparation, for example "dilute-and-shoot", without the requirement for derivatization or conversion before analysis. The fact that no conversion is required means several LC methods can detect GHB and its precursor GBL simultaneously whereas most reported GC methods require additional analysis [99] . Finally, introduction of ultra-high-performance LC (UHPLC), which is more efficient than traditional high-performance LC (HPLC), and automated sample-preparation techniques have also led to the development of highly useful, high-throughput LC-MS-MS methods [34, 68, 99, 102] .
Liquid chromatography with ultraviolet or fluorescence detection Because GHB has no chromophoric group, UVdetection is only possible at low wavelength (220 nm), as reported by De Vriendt et al. [108] . Starting from 60 μL plasma, quantification was possible in the range 10 to 750 μg mL −1 , the LLOQ being 5 to 10-fold higher than for most of the confirmatory methods reported here. Introducing an UV-active or fluorescent group by derivatization should result in enhanced sensitivity and improved certainty of identification, as illustrated by Zacharis et al. [89] . These authors, starting from 500 μL oral fluid, derivatized GHB, producing a highly fluorescent derivative, with the lowest calibrator corresponding to 0.25 μg mL Liquid chromatography-tandem mass spectrometry UHPLC-MS-MS has the potential for shorter run times and improved sensitivity and precision compared with more traditional separation methods, for example HPLC-UVor HPLC-FL; this is also facilitated by the possibility of using a stable isotopically labeled internal standard. For example, Fung et al. [128] modified the LC-UV method described above [108] to a method suitable for LC-MS-MS, and although a slightly higher initial sample volume was required-100 instead of 60 μL-the run time was reduced to 5 min and sensitivity was increased 100-fold (LLOQ 0.1 μg mL
−1
). Also, LC-MS-MS may enable simultaneous analysis of GHB and its precursors, GBL and 1,4-BD [34] , by use of isocratic elution (with 10 % MeOH or acetonitrile) or a slightly rising gradient. Adequate baseline separation of not only GBL and 1,4-BD but also of AHB, BHB and GVL from GHB has been shown [34, 68, 102] . This baseline separation of GHB and its positional isomers is particularly important for adequate identification of GHB using one parent and one product ion. Moreover, because, under some conditions in ESI(+), the molecule might lose water within the instrument source with formation of GBL, it is of interest that the method can distinguish between in-source generated GBL or [GHB − H 2 O] + and actual GBL in a sample [34, 102, 109] . It is interesting to note that in one method [102] this in-source conversion of GHB to GBL resulted in sufficient sensitivity for determination of GHB in whole blood whereas others [34, 109] achieved relatively low (6 %) conversion, which was unsuitable for GHB quantification.
Alternatively, to counter the detection of small m/z ions typical of GHB (m/z parent ion=103), an LC-MS-MS method for GHB in human serum has recently been reported in which quantification was based on fragmentation of adducts formed with components of the mobile phase, more specifically fragmentation of the GHB-sodium acetate adduct in ESI(−) mode (m/z 185) [117] .
Tandem MS has been used in both atmospheric pressure chemical ionization (APCI) and ESI mode, with ESI(+) producing only one product ion with significant abundance and ESI(−) revealing three abundant transition products. The latter is more beneficial for method sensitivity and selectivity [107, 109] . On the other hand, reversed-phase C 18 columns frequently used for GHB separation require acidified mobile phases for better control of the retention of GHB (which, being a weak acid with a pK a of 4.6, is uncharged in acidic mobile phases only) [99] . This may result in restriction to ESI(+) mode only, because the acidic conditions used may reduce the response to GHB in ESI(−) mode [99, 109] . However, Forni et al. reported lower background noise under their chromatographic conditions with the MS-MS operating in ESI(−) as compared with ESI(+) [68] .
Sørensen et al. [109] and Lott et al. [114] suggested use of hydrophilic interaction liquid chromatography (HILIC) to overcome this problem and to improve retention and chromatographic separation of small and polar molecules. HILIC enables chromatography to be performed under neutral conditions, optimal for separation of GHB and its analogues and which also prevents inter-conversion between GHB and GBL [109] . Thus, when a typical C 18 reversed-phase column is used, GHB elutes first, followed by 1,4-BD and GBL, whereas when HILIC is used the order of elution is reversed, which simplifies optimization of the retention time of GHB by adjusting the composition of the mobile phase [109] . Despite these advantages, to reduce the cost of analysis by high-throughput methods, one may opt not to use HILIC methods with acetonitrile, given its higher toxicity and price than, e.g., MeOH. Furthermore, also practical reasons, for example instrumental back-up, may affect the choice between RP and HILIC [99] .
Non-chromatographic techniques
Gong et al. [103] reported a CZE-C 4 D method for analysis of GHB in urine and serum. Although not commonly used for toxicological analysis, this technique is well-suited to determine small ions, for example GHB in the anionic form [118] . Separation and detection of AHB, BHB, and GHB were achieved without preceding extraction or derivatization, merely simple 1:4 dilution with an optimized separation buffer of pH>4.7 to deprotonate the analytes and convert them to the anions. In addition, the more alkaline pH also inhibits conversion of GHB to GBL. The sensitivity of the method was sufficient for discrimination between endogenous and exogenous GHB levels in urine (cut-off 10 μg mL −1 ). Also, the instrumentation is less expensive than that used for the other techniques used in clinical and forensic laboratories, and a portable instrument may enable on-site analysis of urine samples from a suspected GHB intoxication [103] .
Conclusion
To conclude, a variety of screening and confirmation methods are available for analysis of GHB (and analogues if required) in biological fluids. GHB screening and analysis in a toxicological laboratory are mostly performed because of suspected ingestion of this club drug, supported by information from the police or physician, rather than on a routine basis, as is the case for more widely abused drugs, for example cannabinoids, amphetamines, and opioids [54, 116] . However, routine screening has become possible, not only as a result of the commercial availability of an enzymatic kit for GHB suitable for common chemical analyzers but also because of the availability of simpler GC-MS methods and more sophisticated techniques, for example UHPLC-MS-MS, which-when combined with automated sample-preparation proceduresenable high-throughput. To confirm the presence of GHB in biological fluids, GC has remained the most widely used separation technique during the last twenty years, despite the small and polar nature of GHB, which necessitates conversion to GBL or derivatization to a more volatile and stable form. However, LC-based applications coupled to tandem MS are increasingly attracting interest, because they have the advantage of simpler sample-preparation (e.g. no derivatization) or "dilute-and-shoot". Of course, when sample preparation is minimal, matrix effects require special consideration. Furthermore, despite the advantages of reduced workload and shortened analysis time that tandem MS techniques may offer, baseline separation of GHB from GBL and from its isomers AHB and BHB, achieved by adequate chromatography, remains important to avoid interference (for example from GBL formed in the source during MS-MS analysis) [33] . With regard to method sensitivity, GC and LC-based applications have similar LLOQs, but, as Kankaanpää et al. fittingly remarked "the challenge is not to reach as low GHB concentration levels as possible, but to interpret the results correctly being able to make a distinction between use of GHB and endogenous levels" [105] . Indeed, when results have been obtained by use of the screening and confirmation methods discussed above, interpretation is a second challenge for the toxicologist, and analysis of different matrices may be useful for correct interpretation. For example, Kintz et al. [52] suggested analysis of several specimens, including different types of blood and vitreous humor, in the case of a suspected GHB-related death. On the other hand, the question arises whether or not analysis of different matrices, for example oral fluid, sweat, and hair, has the potential to extend detection sensitivity and/or furnish results of more value than those obtained from analysis of more conventional matrices. Furthermore, the newly reported metabolite GHB-glucuronide [74] may be a promising new biomarker of GHB exposure, although additional research is required.
